MKI67 and prostate carcinoma: Ki67 LI increased with decreasing SSTR2 IHC intensity in prostate cancer cells from 2.8±0.4 (strong SSTR2 IHC) over 3.8±0.4 (intermediate SSTR2 IHC) and 5.0±0.2 (weak SSTR2 IHC) to 5.9±0.2 in SSTR2-negative prostate cancers (arithmetical mean ± standard error of the mean, p<0.0001, Figure 2).